Table 2.
Clinical characteristics in the propensity score-matched cohort.
| Variables | Control (n = 23) | Bowel rest (n = 23) | p-value |
|---|---|---|---|
| Age (years) | 85.0 (83–88) | 81.0 (77–92) | 0.758 |
| Males | 5 (21.7) | 7 (30.4) | 0.738 |
| Comorbidities | |||
| Diabetes | 6 (26.1) | 5 (21.7) | 1.000 |
| Malignancy | 5 (21.7) | 4 (17.4) | 1.000 |
| IBD | 1 (4.3) | 2 (8.7) | 1.000 |
| Initial treatment for CDI | |||
| Metronidazole | 19 (82.6) | 19 (82.6) | 1.000 |
| Vancomycin | 4 (17.4) | 4 (17.4) | 1.000 |
| Antibiotic use | |||
| Pre-treatment | 19 (82.6) | 18 (78.3) | 1.000 |
| Post-treatment | 9 (39.1) | 11 (47.8) | 0.767 |
| Medications | |||
| PPI | 13 (56.5) | 11 (47.8) | 0.768 |
| H2RA | 1 (4.3) | 2 (8.7) | 1.000 |
| Probiotics | 13 (56.5) | 15 (65.2) | 0.763 |
| Immunosuppressants | 0 (0) | 2 (8.7) | 0.489 |
| Chemotherapy | 2 (8.7) | 1 (4.3) | 1.000 |
| Vasopressor | 1 (4.3) | 1 (4.3) | 1.000 |
| Tube feeding | 3 (13.0) | 3 (13.0) | 1.000 |
| Surgery | 5 (21.7) | 4 (17.4) | 1.000 |
| ICU stay | 2 (8.7) | 2 (8.7) | 1.000 |
| Laboratory data | |||
| Albumin | 2.40 (2.10–2.75) | 2.40 (2.05–2.80) | 0.700 |
| Creatinine | 0.86 (0.57–1.29) | 0.73 (0.66–1.25) | 0.835 |
| WBC | 8200 (6450–15,000) | 7600 (6600–12,550) | 0.717 |
Data are median (interquartile range) or number (%).
IBD, inflammatory bowel disease; CDI, Clostridioides difficile infection; PPI, proton pump inhibitor; H2RA, histamine H2-receptor antagonist; ICU, intensive care unit; WBC, white blood cell count.